Better Data, Better Decisions: Rethinking Digital Marketing in MedTech
In a highly regulated industry with long sales cycles and complex customer journeys, effective digital marketing requires more than campaigns. It requires a privacy-first approach to data, meaningful measurement, and a clear understanding of what drives business outcomes.
For medical technology companies, digital marketing can be complicated. Privacy regulations limit how companies collect and share data, sales cycles can stretch for months or even a year, and early customer success does not always predict what will work at scale. So how can medtech companies make smarter marketing decisions while protecting sensitive information and demonstrating measurable business impact?
In Episode 283 of the Project Medtech Podcast, Duane Mancini speaks with Aaron Burnett, CEO of Wheelhouse Digital Marketing Group (Wheelhouse DMG), about the intersection of data privacy, performance marketing, and commercialization. Their conversation offers an important reminder: successful digital marketing starts with the right infrastructure and a clear understanding of the business, not simply more advertising.
Turning Privacy Constraints Into a Competitive Advantage
Burnett founded Wheelhouse DMG after experiencing a gap in the agency landscape firsthand. As a marketing executive, he found agencies that were technically capable but lacked the strategic sophistication to connect their work to meaningful business outcomes. He also wanted a different kind of partnership, one focused on achieving results rather than treating every request outside a contract as a new billable engagement.
That vision eventually led Wheelhouse to specialize in healthcare and medtech. Today, the agency combines performance marketing expertise with proprietary technology designed for privacy-sensitive environments. Burnett explained that healthcare and medtech companies cannot necessarily rely on third-party tracking tools in the same way as businesses operating in less regulated industries. Protecting personal health information requires a more deliberate approach to data collection, measurement, and sharing.
Rather than treating those limitations as a barrier, Wheelhouse has developed an approach built around first-party data, controlled data sharing, and privacy-conscious measurement. Its infrastructure replaces conventional third-party tracking with client-specific identifiers, moves measurement server-side, and helps clients bring information from multiple systems together. The goal is not simply to collect more data. It is to understand the customer journey more accurately while maintaining control over what information is collected and shared.
Measuring What Actually Matters
One of the most important distinctions in the conversation is the difference between marketing activity and business performance. In medtech, a click or short-term conversion may be a poor indicator of eventual success. A company could spend months nurturing a prospect before that prospect becomes a customer. Conventional advertising dashboards may not capture that journey or connect it to actual revenue. Wheelhouse addresses this challenge by integrating data across digital marketing, customer relationship management systems, and other business sources. Its team can then use that broader view to identify patterns and develop more meaningful signals for campaign optimization.
Burnett described a process that uses client data to identify characteristics associated with outcomes such as becoming a paying customer. Wheelhouse can model those characteristics and use estimated customer lifetime value as a signal to help advertising platforms optimize campaigns. The larger lesson for medtech leaders is straightforward: marketing metrics are most useful when they connect to the outcomes the business is trying to achieve. Impressions, clicks, and leads can provide context, but they should not replace a thoughtful measurement strategy tied to the customer journey and commercial objectives.
Your First Customers May Not Be Your Next Customers
Another challenge emerges when companies move from early adoption to broader commercialization. A product may gain traction with one specific group of users, leading a company to assume that the same audience will drive future growth. But early adopters may represent only a small part of the potential market.
Burnett shared two approaches for testing those assumptions without relying entirely on internal opinions:
First, conduct user testing with prospective customers. Hearing people describe their needs, frustrations, and reasons for rejecting a product can be more persuasive than presenting a hypothesis based solely on internal analysis.
Second, test variations in advertising creative and messaging. Different concepts can help reveal which audiences respond to particular use cases or value propositions. Those findings can inform future campaigns and challenge assumptions about the ideal customer profile.
The key is to treat commercialization as a learning process. Early traction is valuable, but it should inform further investigation, not prevent it.
Do Your Homework Before Scaling
For companies entering the U.S. market, Burnett offered advice that extends beyond digital marketing: understand the market before investing in promotion. The United States is not a single, uniform audience. Regional differences, cultural expectations, and variations in how healthcare is delivered can influence how people understand and respond to medical technology. Burnett recommends gathering robust market intelligence and conducting consumer research before spending on digital marketing. An agency can help execute a strategy, but it cannot compensate for an organization that has not investigated the market it intends to serve. This is especially relevant for international medtech companies preparing to commercialize in the U.S. Clear market understanding helps inform positioning, messaging, audience selection, and investment decisions. Ultimately, effective marketing depends on the quality of the foundation beneath it: the data, research, strategy, and organizational alignment that guide execution.
Why This Matters
Medtech companies operate at the intersection of innovation, regulation, and patient impact. Their marketing strategies must account for privacy requirements and long, complex buying journeys while still demonstrating measurable business value. Burnett’s perspective reinforces that privacy and performance do not have to be competing priorities. With the right infrastructure and strategy, companies can protect sensitive information while building a clearer picture of their audiences and improving decision-making. It also underscores a broader commercialization principle: scaling successfully requires a willingness to question assumptions, invest in market research, and measure what matters to the business, not just what is easiest to track.
What to Watch
As medtech companies continue to commercialize increasingly connected products and digital health solutions, watch how privacy-first measurement, first-party data strategies, and more sophisticated analytics reshape performance marketing. Pay particular attention to how companies connect marketing activity to downstream commercial outcomes, test assumptions about their ideal customer profiles, and adapt messaging for different markets and user groups. For leaders preparing to scale, the opportunity is not simply to spend more on digital marketing. It is to build a stronger foundation for learning, measurement, and growth.
Listen to Episode 283 of the Project Medtech Podcast here: https://www.projectmedtech.com/projectmedtechpodcast/episode/8f6ae47b/episode-283-aaron-burnett-ceo-at-wheelhouse-dmg-data-driven-marketing-solutions-for-regulated-industries
Helpful Links
Thank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.



Comments